© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Benzbromarone came about in an era when doctors, desperate for new ways to tackle gout, looked beyond the standard options. The search for uricosuric agents led researchers in Europe to tinker with benzofuran derivatives, and eventually, chemists at Sanofi discovered benzbromarone. Its introduction in the late 1970s marked a departure from the familiar allopurinol and probenecid, especially for patients who couldn’t tolerate those drugs. Many folks, especially in Asia and South America, started to rely on it when allopurinol failed, or when chronic kidney issues made other medications riskier. Over the next few decades, the drug's fate ebbed and flowed. Concerns about liver toxicity surfaced in the early 2000s, causing it to vanish from markets like Europe and Australia, though it stuck around in countries where options were fewer or the clinical picture seemed to warrant its use.
Benzbromarone stands out as a uricosuric drug specifically designed to control stubborn cases of hyperuricemia and gout. It’s a small molecule, typically pressed into 50 mg or 100 mg scored tablets, meant to be taken orally once a day. Its role is different from the xanthine oxidase inhibitors, focusing instead on enhancing uric acid excretion through the kidneys. The drug’s shelf life stretches up to three years if kept sealed, dry, and shielded from light. For those allergic to or struggling with allopurinol, benzbromarone can seem like the light at the end of the tunnel—at least where it’s allowed.
As an off-white to pale yellow crystalline powder, benzbromarone isn’t flashy. It weighs in at a molecular formula of C17H12Br2O3 with a molecular weight of about 424.09 g/mol. It melts between 140°C and 145°C, and dissolves slowly in ethanol, acetone, or DMSO, barely budging in water. The presence of two heavy bromine atoms gives it significant heft and stability. Chemists designed this structure to last through the body’s metabolic battleground and emerge ready to block kidney transporters.
Standard pharmacopeial specs demand that each tablet of benzbromarone contains between 95% and 105% of the labeled dose. Impurities like bromobenzene or dibromofuran derivatives have upper limits, usually less than 0.1%. Labels must spell out the risk of liver injury, instructions to monitor transaminases monthly in the first six months, and strict warnings against use in patients with pre-existing liver disease. Packaging often uses blister packs or amber vials, partly to keep out sunlight and moisture, but also to discourage reckless handling.
Factories manufacture benzbromarone by brominating 3-benzylbenzofuran at precise temperatures, followed by refluxing with potassium hydroxide to unlock the right positions on the aromatic ring. The crude material goes through repeated recrystallizations and chromatography to clean out any side-products. Each batch submits to HPLC and NMR analysis for purity, with careful waste collection to keep heavy metal and bromine discharge under control. Most facilities that handle benzbromarone also process related halogenated organics, demanding significant engineering controls.
The chemical backbone of benzbromarone gives it room for experimentation. Introducing different halogens can boost or blunt activity. Quaternization with alkyl groups produces compounds that don’t cross cell membranes as easily, which can matter for toxicity studies. Ongoing research explores esterification at the phenol group to create prodrugs, hoping to bypass the liver’s more dangerous metabolites. In the lab, its bromine groups make it amenable to cross-coupling and Suzuki-type reactions, attracting medicinal chemists seeking new uricosuric drugs with less toxicity.
Pharmacies and reference labs recognize this compound by names like (3,5-dibromo-4-hydroxy-phenyl)-(1-benzofuran-2-yl)-methanone and Urostat. Some regions market it as Desuric, Benzbromaronum, or Urinorm. Chemists also label it as UNII-81DX2R6N2E or simply as benzbromarone, using international nonproprietary names. Safety sheets and regulatory papers will reference its CAS number 3562-84-3.
The most pressing worry in any discussion of benzbromarone centers on liver toxicity. Doctors demand periodic liver enzyme checks, especially during the early stage of therapy. Drug interactions with warfarin and sulfonylureas raise red flags, and warnings extend to anyone with a heavy drinking habit or hepatitis. Manufacturing and compounding require gloves, goggles, and specialized ventilation, given the risk of brominated dust. Spills call for decontamination procedures to keep staff safe and avoid soil or waterway contamination. In healthcare settings, patient monitoring and detailed informed consent form the backbone of responsible use.
Most use of benzbromarone falls squarely within the management of chronic gout and severe hyperuricemia, picking up where allopurinol or febuxostat left patients in trouble. The drug appeals to clinics treating transplant recipients or those with declining kidney function, since its uricosuric action doesn’t rely on xanthine oxidase inhibition. Endocrinologists sometimes experiment with it in metabolic syndrome cases where other urate-lowering drugs fail. Outside medicine, researchers use small quantities to probe renal transporter biology, since benzbromarone blocks the urate transporter URAT1 with striking specificity.
Modern research into benzbromarone remains vibrant, especially in countries fighting rising rates of gout and metabolic disease. Structural analogs in preclinical studies aim to reduce liver toxicity by altering the molecule’s metabolic pathways. Clinical trials keep contrasting its effectiveness to newer uricosurics and old standbys like probenecid, with most studies agreeing that it works especially well when uric acid levels refuse to budge. Pharmacogenetic studies in Japan and China pick apart patient differences in metabolism, seeking a safer, personalized medicine. Attention also drifts toward fixed-dose combinations, pairing small doses of benzbromarone with xanthine oxidase inhibitors in hard-to-treat populations.
Animal models and case reports keep returning to a central point: hepatic injury casts a long shadow. Mice and dogs dosed with high levels show centrilobular necrosis and elevated transaminases, mirroring effects seen in unlucky patients. The main culprit seems to be the O-demethylated metabolite, which hits mitochondrial enzymes necessary for normal liver function. Vigorous screening now weeds out users with a history of hepatitis or unexplained transaminase spikes, but rare fatal outcomes continue to haunt the drug’s reputation. A few scientists have proposed using prodrugs that slide past the first-pass liver metabolism, but none have made it to pharmacy shelves yet.
The story of benzbromarone refuses to fade out. Some regions, still short on better drugs and facing wave after wave of gout patients, advocate for stricter guidelines rather than outright withdrawal. Regulators mull risk mitigation plans, from liver safety registries to genetic testing, hoping to catch the rare but serious cases early. Drug designers remain intrigued by its transporter-blocking power, driving research into new derivatives. If a future molecule manages the same uricosuric punch without the liver risk, it’ll owe much to the hard lessons learned with benzbromarone. In the meantime, careful patient selection, steady monitoring, and honest conversations about risks let doctors weigh its benefits for those with few other options.
Gout feels a lot like being betrayed by your own body. Imagine lying in bed, every movement shooting fire through your big toe. That familiar ache, swelling, and redness signals a gout attack, triggered by uric acid crystals setting up camp in your joints. The goal, every time, stays the same: bring uric acid levels down so these attacks fade away.
Benzbromarone helps people struggling with gout by nudging the body to get rid of extra uric acid. It doesn’t dull pain like anti-inflammatory meds or stop attacks outright, but it chips away at the underlying cause, aiming to prevent gout from returning again and again. As a uricosuric drug, it signals the kidneys to flush out uric acid in the urine, shrinking the chance of those sharp crystals piling up in joints.
Other medications like allopurinol or febuxostat block uric acid production. Some folks can’t take those drugs, maybe due to side effects, intolerance, or rare allergic reactions. Benzbromarone gives another option when older tools just don’t cut it, especially in patients with so-called “under-excreter” gout—a group whose bodies simply don’t clear uric acid fast enough.
Not all countries offer benzbromarone, often because of concerns about rare but serious liver damage. Regulatory agencies keep a close watch, since a handful of patients have developed severe liver issues. Doctors remain cautious, running liver tests before and during treatment, and making sure patients understand the signs they need to watch for.
Living through one gout attack is bad; facing them every few months locks people away from work, sports, or even simple walks. Over time, unchecked uric acid breeds joint damage, kidney stones, and, in some cases, a cycle of pain and misery that stretches for years. On top of that, gout and high uric acid often go hand in hand with other chronic conditions—high blood pressure, diabetes, heart disease—which puts extra weight on families and healthcare systems.
Getting uric acid down to safer levels can make attacks less frequent and help reclaim some freedom from pain. Studies have shown that patients using uricosuric drugs like benzbromarone, especially those with good kidney function, reach those healthier numbers more reliably. In my clinic, I have watched patients walk easier and smile more once their treatment clicked into gear, proving that clearing uric acid does more than lower lab values—it changes daily life.
Not everyone can take benzbromarone. People with kidney stones, certain liver problems, or specific allergies need other solutions. Doctors work with patients to choose carefully, track symptoms, and check in with labs to spot any early warning signs. The experience with benzbromarone shows why practical, personalized care makes the difference—matching the right medicine to the right person, rather than forcing every patient into the same approach.
Access matters, too. As new gout medicines and approaches appear, everyone deserves up-to-date information and transparent discussions about side effects, benefits, costs, and alternatives. Above all, patients want relief they can trust—medicine that does the job without new worries attached. Using benzbromarone with careful attention reflects that deeper value, giving another path toward better days for people stuck in the grip of painful, stubborn gout.
Gout flares up like a thunderstorm in the joints, often catching folks off guard right after a hearty meal or a long night. Behind this sharp pain sits uric acid, a waste product pulled from the breakdown of purines found in food and our bodies. When the kidneys can't clear away enough uric acid, it stacks up in the bloodstream and cements itself into crystals around the joints.
Doctors see this pattern often, especially in people dealing with high blood pressure, extra pounds, rich diets, or some kidney concerns. The main goal in treatment stays simple: drop those uric acid levels and keep gout attacks at bay.
Benzbromarone sits in a group of medicines called uricosurics. These drugs push the kidneys to spill out more uric acid in urine. Instead of letting that acid stick around and crystalize, the medicine encourages the body to get rid of it before trouble starts.
Many folks see names like allopurinol and febuxostat when they first talk to their doctor about gout. These medicines block the body’s ability to make uric acid. Benzbromarone works differently. It doesn’t slow down acid production—it kicks the kidneys into gear, so more leaves the system with each trip to the bathroom.
Plenty of research liens on benzbromarone for patients who can't take or don't respond well to allopurinol or the other drugs. Experts from The European League Against Rheumatism (EULAR) point out its strong track record, especially for people who struggle to move uric acid on their own.
Observations show this drug delivers serious drops in uric acid without dropping people’s quality of life. Real-world numbers push the point home. In one review, nearly three-quarters of patients hit their target acid levels after a regular dose of benzbromarone. Those who bounce from gout crisis to gout crisis might find fresh hope in this approach.
No drug leaves you with only good news. Benzbromarone carries some baggage. The big worry usually traces back to the liver. A rare but real risk of liver damage means doctors need to keep a close watch with regular blood tests. People with pre-existing liver concerns or certain kidney stones steer clear on medical advice.
On the flip side, many patients ran into stomach issues or mild rashes, but most continued treatment without major hurdles. Close conversations with doctors, smart monitoring, and honest talk about any symptoms build a safer path forward.
As a long-time health writer, I’ve seen how much daily pain and lost sleep gout can cause. By focusing not only on lowering uric acid with pharmacy tools, but also tuning up diet, stepping back from sugary drinks, and watching out for dehydration, people stack the odds in their favor.
Benzbromarone has a place for folks who don’t do well on the main drugs or whose kidneys just won’t cooperate. What counts is finding a medical plan that matches the patient, not just the numbers. With ongoing checkups and the right diet changes, most people sidestep the pitfalls and live with far fewer attacks clogging up daily life.
Benzbromarone often shows up as a treatment for gout, especially for folks who haven’t found relief with allopurinol or febuxostat. This medication has a real knack for lowering uric acid levels. Still, it can create some trouble.
Liver complications make up the most serious risk tied to benzbromarone. People using this medicine sometimes face liver injury, which can sneak up as worsening fatigue, yellowed eyes or skin, and dark-colored urine. A study published in Rheumatology flagged that drug-induced liver injury stands out among users, even when patients had normal liver function before starting. Regular blood tests make sense because early signs can fly under the radar. Many clinicians have learned to check liver enzymes often, knowing that early detection can keep someone out of serious trouble. I’ve seen more than one case where just watching those liver markers closely turned something dangerous into an early, manageable bump in the road.
Nausea, stomach discomfort, and diarrhea turn up surprisingly often. In clinic, people share stories about having a tough time sticking with the daily routine, not because the tablet is hard to take, but because their stomachs revolt after a meal. Some need to adjust dosages or take the medicine with food in order to reduce the daily hassle. For many, these stomach problems stay mild and short-lived, but they still mess with the quality of life.
Rash, itching, and redness occasionally pop up within the first few weeks. Most of these reactions clear up on their own, but sometimes, patients have had to stop the drug for good. My experience lines up with recent journal reports, showing that skin complaints pop up quickly, forcing fast decisions about whether to press on or try something else.
Joint pain, tiredness, and headaches also feature in patient stories. Sometimes it’s tough to sort out if it’s the new pill or just the ups and downs of chronic illness, but these patterns repeat enough to catch attention. Watching for changes in mood or sleep can help spot clues that the medicine is affecting more than just uric acid levels.
A lot of doctors stay cautious with benzbromarone, mostly because of the liver risk. In Japan and some European countries, benzbromarone still finds use thanks to thoughtful screening and routine monitoring. Patients with existing liver trouble or a history of allergic drug reactions tend to get steered toward safer options. If someone chooses this drug, regular check-ins can make all the difference between benefit and setbacks. In my practice, setting expectations from day one and catching symptoms early helps people feel empowered, not just worried about their next blood test.
Pre-treatment screening tells a big part of the story. Liver panels and a review of old allergic reactions lay out the risk landscape. Educating patients to report fatigue, jaundice, or rash—not just toughing it out—keeps small problems from becoming emergencies. Doctors who see their patients as teammates in this process get the best results. It’s easy to look for newer, flashier pills, but benzbromarone still holds a place when used with real vigilance and open conversation about side effects. By facing the risks head-on, doctors and patients get a better shot at avoiding setbacks and finding real relief.
Benzbromarone helps a lot of people who deal with gout. It lowers uric acid in the blood by helping the kidneys do their job. That sounds straightforward unless someone has a liver that struggles or kidneys that don’t work well. I’ve talked to patients in clinic rooms who got told about this medicine, but not about the risks that stick out if their health isn’t lined up right for it.
No one with stubborn liver disease should touch benzbromarone. Warnings have come out because liver injuries, some even leading to death, happened for folks on this drug. Anyone with a history of hepatitis, cirrhosis, or abnormal liver tests has higher risk. Even a healthy liver gets checked while taking it, because damage can sneak up. The liver can’t shout out for help, but blood tests catch things before they get ugly. This isn’t just a scare item on the package insert; real reports in medical journals back this up. European regulators have pulled benzbromarone from some markets over liver safety worries.
Moms-to-be and nursing mothers need to avoid this medicine. Safety for unborn babies hasn’t been shown and animal studies suggest possible harm. Uric acid medicines haven’t really been tested in kids or pregnant women for a reason. Gout almost never comes up in pregnancy, but if a woman gets diagnosed, every specialist I know takes benzbromarone off the table fast.
Kidneys clear uric acid with a little extra work, but if someone already has stones or severe kidney disease, benzbromarone isn’t a safe choice. This drug puts more urate into the urine, and that piles up in the tubes if the system’s already clogged. I’ve seen men double over from new stones after starting the drug. If eGFR drops below 30, other options or dietary tweaks come first. For patients curious about numbers, most guidelines say anyone with stage 4 or worse chronic kidney disease finds only trouble here, not relief.
Those with known allergies to benzbromarone or similar drugs absolutely shouldn’t take it. Pairing benzbromarone with certain medicines—like azathioprine, mercaptopurine, or even some anticoagulants—can set off trouble. The liver handles these drugs, so stacking several risky medicines squeezes the safety margin thin. Not every pharmacy flag alerts about benzbromarone, but seasoned specialists catch the red lights quick.
No one should make this call solo. Doctors look at the full health puzzle, not just lab numbers. The whole risk-benefit thing means stopping at liver concerns, pregnancy, kidney failure, or allergy. People with mild gout, mild chronic kidney issues, or who only need a little help lowering uric acid often explore safer paths with their doctors instead. New meds or sometimes just changes in diet do the job without the risks that benzbromarone brings. Looking after your body’s filters—liver and kidneys—takes smart choices and honest talks with a health professional you trust.
Benzbromarone treats gout. The drug works by helping the body get rid of uric acid, which tends to build up and cause those painful flare-ups. Doctors lean on it for patients who can't use or tolerate allopurinol. This medicine isn't the first pick in many countries, mostly from concerns about its effects on the liver, but it still plays an important role around the world, especially in Asia and parts of South America.
Any pill can look the same, but the way people use medication like benzbromarone changes lives. Most adults start on about 50 milligrams a day. The dose may go up slowly, following blood tests, sometimes maxing out at around 100 to 200 milligrams. Doctors keep a close watch on uric acid levels, liver enzymes, and even kidney health. Skipping these checks opens the door for unexpected trouble.
Some folks want a quick fix, imagining higher doses clear gout faster. Truth says otherwise. Going slow means fewer side effects and less risk to the liver. In my own practice, I’ve seen patients frustrated with the pace. Over the years, I've learned that trust in regular lab checks and patience wins the race. I always remind people: more isn’t always better, and small steps help the body adjust.
Doctors usually recommend taking benzbromarone with food or right after a meal. Taking it on an empty stomach sometimes upsets the gut. Sticking to the same time daily builds a routine, reducing missed doses and keeping uric acid steady.
Hydration plays a role, too. Gout and kidney stones can link up. Drinking enough water helps flush uric acid, lowering the risk of kidney stones — a problem nobody wants to add to their week.
Some patients already use medicines like diuretics, which can raise uric acid, working against benzbromarone’s goals. Combining benzbromarone with other drugs that stress the liver, such as methotrexate, may make trouble. People with a history of liver disease need extra caution or a different medicine entirely.
For folks who take supplements or herbal products, transparency with the doctor counts. Health food store advice never matches a full med review from someone who understands drug interactions.
No medicine travels without its own risk. Benzbromarone can cause skin rashes or, rarely, severe liver problems. In my clinic, every few months, we run liver and kidney tests. If yellow eyes, dark urine, or stomach pain show up, that's our cue to pause and test right away. Early changes often clear up if caught fast.
Clear communication between patient and doctor shapes success. In my years around clinics, patients sticking with their follow-up appointments fare best. Handouts and honest talks about symptoms boost awareness. Hospitals could help by arranging calls or reminders for testing.
Gout doesn’t have to control a calendar. With the right dose, teamwork, and attention, benzbromarone stands as a useful tool. Patients do their best work when they know why timing, dose, and follow-up matter and can talk easily with their care team.
| Names | |
| Other names |
Benzbromarone Benzbromaron Desuturan Urinorm Uricosan |
| Pronunciation | /benz-broʊ-ˈmær-oʊn/ |
| Identifiers | |
| CAS Number | [3562-84-3] |
| Beilstein Reference | 1208731 |
| ChEBI | CHEBI:3082 |
| ChEMBL | CHEMBL1433 |
| ChemSpider | 7145 |
| DrugBank | DB13521 |
| ECHA InfoCard | 100.198.969 |
| EC Number | 5.6.1.5 |
| Gmelin Reference | 82867 |
| KEGG | C07314 |
| MeSH | D001584 |
| PubChem CID | 2393 |
| RTECS number | DM1750000 |
| UNII | 9IKM0I6ULW |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C17H12Br2O3 |
| Molar mass | 424.122 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.6 g/cm³ |
| Solubility in water | practically insoluble |
| log P | 2.78 |
| Vapor pressure | 3.6E-13 mmHg at 25°C |
| Acidity (pKa) | 1.90 |
| Basicity (pKb) | 11.01 |
| Magnetic susceptibility (χ) | -61.5e-6 cm³/mol |
| Refractive index (nD) | 1.661 |
| Viscosity | Viscous liquid |
| Dipole moment | 4.75 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 354.3 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | −27.3 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -6631 kJ/mol |
| Pharmacology | |
| ATC code | M04AB03 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes damage to organs through prolonged or repeated exposure. |
| GHS labelling | GHS02, GHS07, GHS08 |
| Pictograms | GHS06, GHS08 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. H351: Suspected of causing cancer. H411: Toxic to aquatic life with long lasting effects. |
| Precautionary statements | P264, P270, P301+P312, P330, P501 |
| Flash point | 143.4°C |
| Lethal dose or concentration | LD50 (rat, oral): 880 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse oral 520 mg/kg |
| NIOSH | RX8220000 |
| PEL (Permissible) | Not established |
| REL (Recommended) | 0.5–1 mg/kg/daily |
| IDLH (Immediate danger) | Not Established |
| Related compounds | |
| Related compounds |
Benzarone Benzfluorone |
